These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8977066)

  • 1. Clinical use of prostate-specific antigen and prostate-specific antigen density in the staging of patients with cancer of the prostate.
    Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
    Eur Urol; 1996; 30(4):451-7. PubMed ID: 8977066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
    Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
    Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels.
    Kurita Y; Suzuki A; Masuda H; Ushiyama T; Suzuki K; Fujita K
    Eur Urol; 1998; 33(1):32-8. PubMed ID: 9471039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The value of PSA density for the diagnosis of prostatic cancer and for the indication of radical prostatectomy].
    Doublet JD; Ciofu C; Fouret P; Gattegno B; Thibault P
    Prog Urol; 1995 Apr; 5(2):211-9, 220; discussion 219-20. PubMed ID: 7536529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.
    Brassell SA; Kao TC; Sun L; Moul JW
    Urology; 2005 Dec; 66(6):1229-33. PubMed ID: 16360448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer.
    Hara I; Miyake H; Hara S; Yamanaka N; Ono Y; Eto H; Takechi Y; Arakawa S; Kamidono S
    BJU Int; 2001 Jul; 88(1):53-7. PubMed ID: 11446846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
    Zlotta AR; Djavan B; Petein M; Susani M; Marberger M; Schulman CC
    J Urol; 1998 Dec; 160(6 Pt 1):2089-95. PubMed ID: 9817330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels.
    Furuya Y; Ohta S; Sato N; Kotake T; Sugano I; Nagao K; Masai M
    Anticancer Res; 2001; 21(2B):1317-20. PubMed ID: 11396206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer?
    Giannarini G; Scott CA; Moro U; Pertoldi B; Beltrami CA; Selli C
    Urol Oncol; 2008; 26(4):353-60. PubMed ID: 18367100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
    Catalona WJ; Southwick PC; Slawin KM; Partin AW; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Loveland KG; Bray KR
    Urology; 2000 Aug; 56(2):255-60. PubMed ID: 10925089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy.
    Masai M; Ito H; Kotake T; Nagao K
    Int J Urol; 1996 Mar; 3(2):118-23. PubMed ID: 8689505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PSA volume quotient: an additional parameter in diagnosis of locally confined prostate cancer].
    Gottfried HW; Kleinschmidt K; Flohr P; Miller K; Hautmann R
    Urologe A; 1993 Nov; 32(6):455-9. PubMed ID: 7506850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer.
    Martínez M; Navarro S; Medina P; Villavicencio H; Rioja L; Solsona E; Estellés A; Aznar J; Jiménez-Cruz JF; España F
    Eur Urol; 2003 Jun; 43(6):609-14. PubMed ID: 12767360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
    Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
    J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer.
    Aslan G; Irer B; Kefi A; Celebi I; Yörükoğlu K; Esen A
    Int Urol Nephrol; 2005; 37(3):511-4. PubMed ID: 16307332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.